Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 4/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100418 | 0.85 | SYK (0.54) | SYKPPARACTSSCTSLATM | |
| SCHEMBL10100484 | 0.84 | SYK (0.50) | SYKPPARACTSSCTSLATM | |
| SCHEMBL10100501 | 0.81 | SYK (0.50) | SYKPPARANPC1RAB9ACTSS | |
| SCHEMBL887438 | 0.81 | CTSS (0.40) | PPARANPC1RAB9ACTSSCTSL | |
| SCHEMBL10100478 | 0.81 | SYK (0.47) | SYKPPARACTSSCTSLATM | |
| SCHEMBL13168658 | 0.81 | NPC1 (0.52) | NPC1RAB9ACTSSCTSLATM | |
| SCHEMBL10100505 | 0.81 | SYK (0.49) | SYKPPARACTSSCTSLATM | |
| SCHEMBL10100486 | 0.81 | SYK (0.49) | SYKPPARACTSSCTSLATM | |
| SCHEMBL648574 | 0.80 | POLB (0.58) | SYKPPARACTSSCTSLATM | |
| SCHEMBL1463134 | 0.80 | POLB (0.58) | SYKPPARACTSSCTSLATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097750-B2 | Highly enantioselective, converting aromatic and aliphatic aldehydes into optically active aryl and alkyl beta -amino acids | BRANDEIS UNIVERSITY (US) | 2012-01-17 | — | — | US | disclosed |
| US-20080228000-A1 | Cinchona Alkaloid-Catalyzed Asymmetric Mannich Reactions | BRANDEIS UNIVERSITY (US) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080228000-A1 | Cinchona Alkaloid-Catalyzed Asymmetric Mannich Reactions | MANBA, MAN2A1, ASNS | SYK 4085/4885PPARA 2259/4885NPC1 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.